Correlation between angiotensin-converting enzyme, vascular endothelial growth factor, and matrix metalloproteinase-9 in the vitreous of eyes with diabetic retinopathy

American Journal of Ophthalmology

Volumn 141, Issue 1, 2006, Pages

  Ishizaki, Eisuke ^a   Takai, Shinji ^a   Ueki, Mari ^a   Maeno, Takatoshi ^a   Maruichi, Midori ^a   Sugiyama, Tetsuya ^a   Oku, Hidehiro ^a   Ikeda, Tsunehiko ^a   Miyazaki, Mizuo ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; DIPEPTIDYL CARBOXYPEPTIDASE; GELATINASE B; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CORRELATION FUNCTION; DIABETIC RETINOPATHY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SUBSTRATE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RETINA MACULA LUTEA; TISSUE LEVEL; VITREORETINOPATHY; VITREOUS BODY;

EID: 29544450595     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2005.08.066     Document Type: Article

References (34)

1. V.J. Dzau, J.R. Ingelfinger, R.E. Pratt Regulation of tissue renin and angiotensin gene expressions J Cardiovasc Pharmacol 8 suppl 10 1986 S11 S16
2. M. Paul, J. Wagner, V.J. Dzau Gene expression of the renin angiotensin systems in human tissues quantitative analysis by the polymerase chain reaction J Clin Invest 91 1993 2058 2064
3. G. Ferrari-Dileo, E.B. Davis, D.R. Anderson Angiotensin binding sites in bovine and human retinal blood vessels Invest Ophthalmol Vis Sci 28 1987 1747 1751
4. J. Wagner, A.H. Jan Danser, F.H. Derkx Demonstration of renin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye evidence for an intraocular renin-angiotensin system Br J Ophthalmol 80 1996 159 163
5. B. Matulla, G. Streit, S. Pieh Effects of losartan on cerebral and ocular circulation in healthy subjects Br J Clin Pharmacol 44 1997 369 375
6. K. Krejcy, M. Wolzt, C. Kreuzer Characterization of angiotensin-II effects on cerebral and ocular circulation by noninvasive methods Br J Clin Pharmacol 43 1997 501 508
7. A.H. Danser, F.H. Derkx, P.J. Admiraal, J. Deinum, P.T. de Jong, M.A. Schalekamp Angiotensin levels in the eye Invest Ophthalmol Vis Sci 35 1994 1008 1018
8. R.E. Gilbert, D. Vranes, J.L. Berka Vascular endothelial growth factor and its receptors in control and diabetic rat eyes Lab Invest 78 1998 1017 1027
9. Y. Okada, I. Yamanaka, T. Sakamoto Increased expression of angiotensin-converting enzyme in retinas of diabetic rats Jpn J Ophthalmol 45 2001 585 591
10. L.P. Aiello, E.A. Pierce, E.D. Foley Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins Proc Natl Acad Sci U S A 92 1995 10457 10461
11. A. Otani, H. Takagi, H. Oh Angiotensin II-stimulated vascular endothelial growth factor expression in bovine retinal pericytes Invest Ophthalmol Vis Sci 41 2000 1192 1199
12. H. Funatsu, H. Yamashita, Y. Nakanishi, S. Hori Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy Br J Ophthalmol 86 2002 311 315
13. T. Kida, T. Ikeda, M. Nishimura Renin-angiotensin system in proliferative diabetic retinopathy and its gene expression in cultured human muller cells Jpn J Ophthalmol 47 2003 36 41
14. M. Maruichi, H. Oku, S. Takai Measurement of activities in two different angiotensin II generating systems, chymase and angiotensin-converting enzyme, in the vitreous fluid of vitreoretinal diseases a possible involvement of chymase in the pathogenesis of macular hole patients Curr Eye Res 29 2004 321 325
15. C.J. Moravski, D.J. Kelly, M.E. Cooper Retinal neovascularization is prevented by blockade of the renin-angiotensin system Hypertension 36 2000 1099 1104
16. R.D. Higgins, Y. Yan, Y. Geng, J. Sharma, S.M. Barr Captopril and vascular endothelial growth factor in a mouse model of retinopathy Curr Eye Res 27 2003 123 129
17. I.M. Hogeboom van Buggenum, B.C. Polak Angiotensin converting enzyme inhibiting therapy is associated with lower vitreous vascular endothelial growth factor concentrations in patients with proliferative diabetic retinopathy Diabetologia 45 2002 203 209
18. P. Rouet-Benzineb, B. Gontero, P. Dreyfus, C. Lafuma Angiotensin II induces nuclear factor-κB activation in cultured neonatal rat cardiomyocytes through protein kinase C signaling pathway J Mol Cell Cardiol 32 2000 1767 1778
19. D. Reinhardt, H.H. Sigusch, J. Hensse, S.C. Tyagi, R. Korfer, H.R. Figulla Cardiac remodelling in end stage heart failure upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP Heart 88 2002 525 530
20. M. Jin, K. Kashiwagi, Y. Iizuka, Y. Tanaka, M. Imai, S. Tsukahara Matrix metalloproteinases in human diabetic and nondiabetic vitreous Retina 21 2001 28 33
21. H. Kosano, T. Okano, Y. Katsura ProMMP-9(92 kDa gelatinase) in vitreous fluid of patients with proliferative diabetic retinopathy Life Sci 64 1999 2307 2315
22. H. Wang, J.A. Keiser Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells role of flt-1 Circ Res 83 1998 832 840
23. Y. Sato, M. Abe, K. Tanaka Signal transduction and transcriptional regulation of angiogenesis Adv Exp Med Biol 476 2000 109 115
24. G.S. Robinson, E.A. Pierce, S.L. Rook, E. Foley, R. Webb, L.E. Smith Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy Proc Natl Acad Sci U S A 93 1996 4851 4856
25. R.B. Bhisitkul, G.S. Robinson, R.S. Moulton, K.P. Claffey, E.S. Gragoudas, J.W. Miller An antisense oligodeoxynucleotide against vascular endothelial growth factor in a nonhuman primate model of iris neovascularization Arch Ophthalmol 123 2005 214 219
26. A. Das, A. McLamore, W. Song, P.G. McGuire Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor Arch Ophthalmol 117 1999 498 503
27. M. Lonchampt, L. Pennel, J. Duhault Hyperoxia/normoxia-driven retinal angiogenesis in mice a role for angiotensin II Invest Ophthalmol Vis Sci 42 2001 429 432
28. N. Chaturvedi, A.K. Sjolie, J.M. Stephenson Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes Lancet 351 1998 28 31
29. E.J. Rockwood, F. Fantes, E.B. Davis, D.R. Anderson The response of retinal vasculature to angiotensin Invest Ophthalmol Vis Sci 28 1987 676 682
30. W.H. Constad, P. Fiore, C. Samson, A.A. Cinotti Use of an angiotensin converting enzyme inhibitor in ocular hypertension and primary open-angle glaucoma Am J Ophthalmol 105 1988 674 677
31. A. Otani, H. Takagi, K. Suzuma, Y. Honda Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells Circ Res 82 1998 619 628
32. Y. Nagisa, A. Shintani, S. Nakagawa The angiotensin II receptor antagonist candesartan cilexetil (TCV-116) ameliorates retinal disorders in rats Diabetologia 44 2001 883 888
33. N. Nagai, K. Noda, T. Urano Selective suppression of pathologic, but not physiologic, retinal neovascularization by blocking the angiotensin II type 1 receptor Invest Ophthalmol Vis Sci 46 2005 1078 1084
34. N. Chaturvedi, A.K. Sjoelie, A. Svensson The Diabetic Retinopathy Candesartan Trials (DIRECT) Programme rationale and study design J Renin Angiotensin Aldosterone Syst 3 2002 255 261